Drug Profile
Research programme: CNS disorders therapies - Genopia Biomedical
Latest Information Update: 24 Feb 2010
Price :
$50
*
At a glance
- Originator GENOPIA Biomedical
- Class
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 24 Feb 2010 Discontinued - Preclinical for Multiple sclerosis in Germany (unspecified route)
- 11 Aug 2004 Preclinical trials in Multiple sclerosis in Germany (unspecified route)